It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 3 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 6 TA indicator(s) are bullish.
LLY (@Pharmaceuticals: Major) experienced а +2.33% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.41%. For the same industry, the average monthly price growth was +2.96%, and the average quarterly price growth was +9.39%.
LLY is expected to report earnings on Oct 30, 2024.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
LLY | ||
---|---|---|
OUTLOOK RATING 1..100 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | |
SMR RATING 1..100 | 18 | |
PRICE GROWTH RATING 1..100 | 44 | |
P/E GROWTH RATING 1..100 | 27 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LLY | SIXA | |
---|---|---|
RSI ODDS (%) | N/A | 4 days ago69% |
Stochastic ODDS (%) | 4 days ago77% | 4 days ago85% |
Momentum ODDS (%) | 4 days ago50% | 4 days ago83% |
MACD ODDS (%) | 4 days ago53% | 4 days ago73% |
TrendWeek ODDS (%) | 4 days ago72% | 4 days ago86% |
TrendMonth ODDS (%) | 4 days ago72% | 4 days ago87% |
Advances ODDS (%) | 5 days ago72% | 4 days ago84% |
Declines ODDS (%) | 11 days ago52% | 11 days ago66% |
BollingerBands ODDS (%) | 4 days ago68% | 4 days ago90% |
Aroon ODDS (%) | 4 days ago74% | 4 days ago84% |
A.I.dvisor tells us that SIXA and ORCL have been poorly correlated (+15% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SIXA and ORCL's prices will move in lockstep.
Ticker / NAME | Correlation To SIXA | 1D Price Change % | ||
---|---|---|---|---|
SIXA | 100% | +0.52% | ||
ORCL - SIXA | 15% Poorly correlated | +0.40% | ||
LLY - SIXA | 14% Poorly correlated | -1.21% | ||
CRM - SIXA | 13% Poorly correlated | +0.47% | ||
AAPL - SIXA | 11% Poorly correlated | -0.12% | ||
COST - SIXA | 10% Poorly correlated | +0.11% | ||
More |